EUVIMEDEUVIMED entdecken
LeitlinieSystematische ÜbersichtOpen Access · CC BY 4.0

Australasian hidradenitis suppurativa management guidelines

John Frew iD, Annika Smith, Pablo Fernandez Penas, Elisabeth Ellis, Peter Foley, Diana Rubel, Erin McMeniman, Gillian Marshman, Helen Saunders, Emma Veysey, Jenny Nicolopolous, Linda Spelman und 1 weitere

Australasian Journal of Dermatology · 2025

DOI: 10.1111/ajd.14388 ↗

Kurz gefasst

Leitlinie in der Zeitschrift Australasian Journal of Dermatology, 2025. Verfasst von John Frew und 12 weiteren Autor:innen. Beteiligte Einrichtung: The Skin Hospital, Sydney, New South Wales, Australia. Hauptthemen laut MEDLINE: Hidradenitis Suppurativa. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 124 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Hidradenitis Suppurativa is a burdensome inflammatory skin disease with significant quality of life impact. These management guidelines were developed to direct appropriate clinical management in the Australasian context. A systematic review was used for the basis of the consensus guidelines. Thirteen clinical experts were involved in a modified Delphi consensus process to develop the guidelines and treatment algorithms. Overall management strategies include appropriate severity assessment of disease and comorbidities, multimodal therapy with systemic and local treatments, and evidence‐based progression along the therapeutic ladder in the event of inadequate response. Sequential monotherapy with antibiotics and/or single agent therapy is discouraged and aggressive treatment of moderate to severe disease to capture the window of opportunity is highly emphasised. Specific considerations in the setting of disease comorbidities, pregnancy and breastfeeding are also addressed. Overall, the complex nature of HS requires a complex and multimodal therapeutic response with medical, physical and surgical therapies to achieve best patient outcomes.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hidradenitis SuppurativaHumansAnti-Bacterial AgentsFemaleSeverity of Illness IndexDelphi TechniqueAustralasiaCombined Modality TherapyAlgorithmsPregnancy

Stichwörter der Autor:innen

acne Inversaconsensusguidelineshidradenitis suppurativa

Substanzen

Anti-Bacterial Agents

Autor:innen und Institutionen

  • The Skin Hospital, Sydney, New South Wales, Australia.
  • Department of Dermatology, Liverpool Hospital, Sydney, New South Wales, Australia.
  • University of New South Wales, Sydney, New South Wales, Australia.
  • Department of Dermatology, Westmead Hospital, Sydney, New South Wales, Australia.
  • University of Sydney, Sydney, New South Wales, Australia.
  • Flinders Medical Centre, Adelaide, South Australia, Australia.

ORCID-Profile: John Frew

Zitieren

APA

Frew, J., Smith, A., Penas, P. F., Ellis, E., Foley, P., Rubel, D., McMeniman, E., Marshman, G., Saunders, H., Veysey, E., Nicolopolous, J., Spelman, L., & Gebauer, K. (2025). Australasian hidradenitis suppurativa management guidelines. Australasian Journal of Dermatology. https://doi.org/10.1111/ajd.14388

Vancouver

Frew J, Smith A, Penas PF, Ellis E, Foley P, Rubel D, et al. Australasian hidradenitis suppurativa management guidelines. Australasian Journal of Dermatology. 2025. doi:10.1111/ajd.14388

BibTeX
@article{Frew2025,
  author = {Frew, John and Smith, Annika and Penas, Pablo Fernandez and Ellis, Elisabeth and Foley, Peter and Rubel, Diana and McMeniman, Erin and Marshman, Gillian and Saunders, Helen and Veysey, Emma and Nicolopolous, Jenny and Spelman, Linda and Gebauer, Kurt},
  title = {Australasian hidradenitis suppurativa management guidelines},
  journal = {Australasian Journal of Dermatology},
  year = {2025},
  doi = {10.1111/ajd.14388}
}
Kostenlos starten →